[go: up one dir, main page]

RU2002111657A - HEXAHYDROFURO [2,3-b] FURAN-3-IL-N- {3 - [(1,3-BENZODIOXOL-5-ILSULFONIL) (Isobutyl) AMINO] -1-BENZYL-2-HYDROXYPROPYL} CARBAMRUS KARINOBI - Google Patents

HEXAHYDROFURO [2,3-b] FURAN-3-IL-N- {3 - [(1,3-BENZODIOXOL-5-ILSULFONIL) (Isobutyl) AMINO] -1-BENZYL-2-HYDROXYPROPYL} CARBAMRUS KARINOBI

Info

Publication number
RU2002111657A
RU2002111657A RU2002111657/04A RU2002111657A RU2002111657A RU 2002111657 A RU2002111657 A RU 2002111657A RU 2002111657/04 A RU2002111657/04 A RU 2002111657/04A RU 2002111657 A RU2002111657 A RU 2002111657A RU 2002111657 A RU2002111657 A RU 2002111657A
Authority
RU
Russia
Prior art keywords
compound according
retrovirus
mammals
compound
inhibiting
Prior art date
Application number
RU2002111657/04A
Other languages
Russian (ru)
Other versions
RU2247123C2 (en
Inventor
Пит Том Берт Поль Вигеринк
Гуангианг ВАНГ
Майкл ЭЙССЕНСТЭТ
Джон В. ЭРИКСОН
Original Assignee
Тиботек Фармасьютикалз Лтд.
ДЗЕ ГАВЕРМЕНТ ОФ ДЗЕ ЮНАЙТЕД СТЕЙТС ОФ АМЕРИКА, репрезентед бай ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМЭН СЕРВИСИЗ, НЭШНЛ ИНСТИТЬЮТС ОФ ХЕЛТ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикалз Лтд., ДЗЕ ГАВЕРМЕНТ ОФ ДЗЕ ЮНАЙТЕД СТЕЙТС ОФ АМЕРИКА, репрезентед бай ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМЭН СЕРВИСИЗ, НЭШНЛ ИНСТИТЬЮТС ОФ ХЕЛТ filed Critical Тиботек Фармасьютикалз Лтд.
Publication of RU2002111657A publication Critical patent/RU2002111657A/en
Application granted granted Critical
Publication of RU2247123C2 publication Critical patent/RU2247123C2/en

Links

Claims (18)

1. Соединение, представленное формулой1. The compound represented by formula
Figure 00000001
Figure 00000001
 его N-оксид, соль, сложный эфир, стереоизомерная форма, рацемическая смесь, пролекарство или метаболит.its N-oxide, salt, ester, stereoisomeric form, racemic mixture, prodrug or metabolite. 2. Соединение по п.1 в энантиомерно чистой форме.2. The compound according to claim 1 in enantiomerically pure form. 3. Соединение по п.1 или 2, отличающееся тем, что соединение представляет собой3. The compound according to claim 1 or 2, characterized in that the compound is a
Figure 00000002
Figure 00000002
 его N-оксид, соль, сложный эфир, пролекарство или метаболит.its N-oxide, salt, ester, prodrug or metabolite. 4. Соединение по любому из пп.1-3 в форме фармацевтически переносимой соли.4. The compound according to any one of claims 1 to 3 in the form of a pharmaceutically tolerated salt. 5. Соединение по любому из пп.1-4 в форме пролекарства.5. The compound according to any one of claims 1 to 4 in the form of a prodrug. 6. Фармацевтическая композиция, содержащая эффективное количество, по крайней мере, одного соединения по любому из пп.1-5 и фармацевтически переносимый наполнитель.6. A pharmaceutical composition comprising an effective amount of at least one compound according to any one of claims 1 to 5 and a pharmaceutically acceptable excipient. 7. Способ ингибирования ретровирусной протеазы у млекопитающих, инфицированных указанным ретровирусом, включающий введение соединения по любому из пп.1-5 в количестве, ингибирующем протеазу, указанным нуждающимся в этом млекопитающим.7. A method of inhibiting a retroviral protease in mammals infected with said retrovirus, comprising administering a compound according to any one of claims 1 to 5 in an amount that inhibits the protease indicated by the mammal in need. 8. Способ лечения или борьбы с инфекцией или заболеванием, связанным с ретровирусной инфекцией, у млекопитающих, включающий введение эффективного количества, по крайней мере, одного соединения по любому из пп.1-5 указанным млекопитающим.8. A method of treating or combating an infection or disease associated with a retroviral infection in mammals, comprising administering an effective amount of at least one compound according to any one of claims 1 to 5 to said mammals. 9. Способ по п.7 или 8, отличающийся тем, что указанным млекопитающим является человек.9. The method according to claim 7 or 8, characterized in that said mammal is a human. 10. Способ ингибирования репликации ретровируса, включающий воздействие на ретровирус эффективным количеством, по крайней мере, одного соединения по любому из пп.1-5.10. A method of inhibiting retrovirus replication, comprising exposing the retrovirus to an effective amount of at least one compound according to any one of claims 1-5. 11. Способ по п.7 или 8, или 10, отличающийся тем, что ретровирус представляет собой вирус иммунодефицита человека (ВИЧ).11. The method according to claim 7 or 8, or 10, characterized in that the retrovirus is a human immunodeficiency virus (HIV). 12. Способ по п.11, отличающийся тем, что вирус ВИЧ представляет собой штамм, резистентный ко многим лекарственным препаратам.12. The method according to claim 11, characterized in that the HIV virus is a strain resistant to many drugs. 13. Соединение по любому из пп.1-5, для применения в качестве лекарства.13. The compound according to any one of claims 1 to 5, for use as a medicine. 14. Соединения по любому из пп.1-5 в качестве активного ингредиента лекарственного препарата для лечения или борьбы с инфекцией или заболеванием, связанным с ретровирусной инфекцией, у млекопитающих.14. Compounds according to any one of claims 1 to 5 as an active ingredient of a medicament for treating or combating an infection or disease associated with a retroviral infection in mammals. 15. Соединения по любому из пп.1-5 в качестве активного ингредиента лекарственного препарата для ингибирования ретровирусной протеазы у млекопитающих, инфицированных указанным ретровирусом.15. Compounds according to any one of claims 1 to 5 as an active ingredient of a medicament for inhibiting a retroviral protease in mammals infected with said retrovirus. 16. Соединения по любому из пп.1-5 в качестве активного ингредиента лекарственного препарата для ингибирования репликации ретровируса.16. Compounds according to any one of claims 1 to 5 as an active ingredient of a medicament for inhibiting retrovirus replication. 17. Применение по любому из пп.14-16, отличающееся тем, что ретровирус представляет собой вирус иммунодефицита человека (ВИЧ).17. The use according to any one of paragraphs.14-16, characterized in that the retrovirus is a human immunodeficiency virus (HIV). 18. Применение по любому из пп. 14-16, отличающееся тем, что вирус ВИЧ представляет собой штамм, резистентный ко многим лекарственным препаратам.18. The use according to any one of paragraphs. 14-16, characterized in that the HIV virus is a strain resistant to many drugs.
RU2002111657/04A 1999-10-06 2000-10-06 Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5- yl- sulfonyl)(isobu tyl)amino]-1-benzyl-2-hydroxypropyl}carbamate, pharmaceutical composition based on thereof, methods for inhibition and method for treatment RU2247123C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15785099P 1999-10-06 1999-10-06
US60/157,850 1999-10-06

Publications (2)

Publication Number Publication Date
RU2002111657A true RU2002111657A (en) 2003-12-10
RU2247123C2 RU2247123C2 (en) 2005-02-27

Family

ID=22565540

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002111657/04A RU2247123C2 (en) 1999-10-06 2000-10-06 Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5- yl- sulfonyl)(isobu tyl)amino]-1-benzyl-2-hydroxypropyl}carbamate, pharmaceutical composition based on thereof, methods for inhibition and method for treatment

Country Status (25)

Country Link
US (2) US6649651B1 (en)
EP (1) EP1222192B8 (en)
JP (1) JP4951179B2 (en)
KR (1) KR100792391B1 (en)
CN (1) CN1191256C (en)
AP (1) AP1459A (en)
AT (1) ATE398623T1 (en)
AU (1) AU781656B2 (en)
BR (1) BR0014602A (en)
CA (1) CA2386850C (en)
CZ (1) CZ300031B6 (en)
DE (1) DE60039244D1 (en)
DK (1) DK1222192T3 (en)
ES (1) ES2307533T3 (en)
HU (1) HU228938B1 (en)
IL (2) IL149005A0 (en)
MX (1) MXPA02003607A (en)
NO (1) NO327996B1 (en)
NZ (1) NZ518580A (en)
OA (1) OA12053A (en)
PL (1) PL204924B1 (en)
RU (1) RU2247123C2 (en)
SK (1) SK287153B6 (en)
WO (1) WO2001025240A1 (en)
ZA (1) ZA200202655B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149005A0 (en) * 1999-10-06 2002-11-10 Us Gov Health & Human Serv Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
WO2002081478A2 (en) * 2001-04-09 2002-10-17 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
IL160166A0 (en) * 2001-09-10 2004-07-25 Tibotec Pharm Ltd Method for the preparation of hexahydro-furo[2,3-b] furan-3-ol
WO2003064406A1 (en) * 2002-01-07 2003-08-07 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
SI1517899T1 (en) 2002-05-17 2008-02-29 Tibotec Pharm Ltd Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
CN101445493A (en) * 2002-08-02 2009-06-03 泰博特克药品有限公司 Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
AU2003275675A1 (en) 2002-12-27 2004-07-29 Sumitomo Chemical Company, Limited Process for producing hexahydrofurofuranol derivative, intermediate thereof and process for producing the same
CN1953964A (en) 2004-03-11 2007-04-25 塞阔伊亚药品公司 Resistance-repellent retroviral protease inhibitors
TWI383975B (en) 2004-03-31 2013-02-01 悌柏泰克醫藥有限公司 Method for preparing (3R, 3aS, 6aR) hexahydro-furo[2,3-b]furan-3-ol
KR100698291B1 (en) * 2004-12-29 2007-03-22 엘지전자 주식회사 Lighting system
JP5260965B2 (en) 2005-02-25 2013-08-14 テイボテク・フアーマシユーチカルズ Protease inhibitor precursor synthesis
FR2888849B1 (en) * 2005-07-19 2007-10-05 Pierre Fabre Medicament Sa PROCESS FOR THE PREPARATION OF 4B-AMINO-4'-DEMETHYL-4-DESOXYPODOPHYLLOTOXIN
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2007277253A1 (en) * 2006-07-24 2008-01-31 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
CN101541775B (en) 2006-11-09 2011-12-28 泰博特克药品有限公司 Preparation method of hexahydrofuro[2,3-b]furan-3-ol
EP2491785A1 (en) * 2006-11-21 2012-08-29 Purdue Research Foundation Method and compositions for treating HIV infections
ES2602784T3 (en) 2007-02-23 2017-02-22 Gilead Sciences, Inc. Modulators of the pharmacokinetic properties of therapeutic agents
US7981929B2 (en) 2007-03-16 2011-07-19 Sequoia Pharmaceuticals, Inc. Benzofuran derived HIV protease inhibitors
CN101796040A (en) 2007-07-06 2010-08-04 吉里德科学公司 Modulators of the Pharmacokinetic Properties of Therapeutic Agents
JP5629585B2 (en) 2008-01-04 2014-11-19 ギリアード サイエンシーズ， インコーポレイテッド Inhibitor of cytochrome P450
EP2244571A4 (en) 2008-01-17 2014-02-19 Purdue Research Foundation SMALL INHIBITORY MOLECULES OF HIV PROTEASES
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
EP2304043A4 (en) * 2008-07-09 2012-05-30 Purdue Research Foundation HIV PROTEASE INHIBITORS AND METHODS OF USE
AU2010338425B2 (en) 2009-12-21 2015-07-23 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
PL2643326T3 (en) 2010-11-23 2017-06-30 Mylan Laboratories, Limited Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol
EP2883858B1 (en) 2012-08-09 2017-12-27 Sumitomo Chemical Company Limited Method for producing hexahydrofurofuranol derivative
CN103664976B (en) * 2013-12-12 2015-11-04 惠州市莱佛士制药技术有限公司 The preparation method of a kind of cis hexahydro furyl also [2,3-b] furan-3-ol

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463104A (en) * 1992-08-25 1995-10-31 G. D. Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2123065T3 (en) * 1992-08-25 1999-01-01 Searle & Co HYDROXYETHYLAMINE-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS.
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
EP0715618B1 (en) * 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
UA49803C2 (en) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко METHOD FOR TREATMENT OF RETROVIRAL INFECTIONS
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
ATE500823T1 (en) * 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-INFECTED MAMMALS
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
IL149005A0 (en) * 1999-10-06 2002-11-10 Us Gov Health & Human Serv Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor

Similar Documents

Publication Publication Date Title
RU2002111657A (en) HEXAHYDROFURO [2,3-b] FURAN-3-IL-N- {3 - [(1,3-BENZODIOXOL-5-ILSULFONIL) (Isobutyl) AMINO] -1-BENZYL-2-HYDROXYPROPYL} CARBAMRUS KARINOBI
RU2329050C2 (en) Combination of cytochrome-p450-dependent protease inhibitors
CA2386850A1 (en) Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
US9339470B2 (en) Anti-retroviral combination
WO2011088561A1 (en) Anti-viral compounds and compositions
JP2009535352A5 (en)
BR0010498A (en) Modern drug compositions based on anticholinergically active and beta-mimetic compounds
HUP9802339A2 (en) Pharmaceutical formulations containing darifenacin
RU2004129324A (en) APPLICATIONS OF BISPHOSPHONIC ACIDS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
JP2021001189A5 (en)
RU95121731A (en) APPLICATION OF RILUZOL FOR THE TREATMENT OF NEURO AIDS AND THE METHOD FOR PRODUCING A MEDICINE
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
JP2016528240A (en) Medicament having a medicinal combination of doltegravir, emtricitabine and tenofovir
ES2298286T3 (en) FORMULATIONS OF SELF-EMULSIONING ORAL DOSE OF PROTEASA INHIBITORS OF PIRANONA.
RU2002105485A (en) The use of mycophenolate mofetil in combination with PEG-interferon-α (PEG-IFN-α)
Naesens et al. In vivo antiretroviral efficacy of oral bis (POM)-PMEA, the bis (pivaloyloxymethyl) prodrug of 9-(2-phosphonylmethoxyethyl) adenine (PMEA)
RU2011111117A (en) TREATMENT OF AUTOIMMUNE DISEASES
RU2007132971A (en) METHODS AND MATERIALS WITH TRANS-CLOMIPHENES FOR TREATMENT OF MEN'S INFERTILITY
AU2018239257B2 (en) HIV post-exposure prophylaxis
JP2002533470A5 (en)
TR200103144T2 (en) New compounds
ATE192926T1 (en) COMPOSITION CONTAINING FLAVOPEREIRINE AND ITS USE IN THE TREATMENT AGAINST HIV VIRUSES
BRPI0415322A (en) antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life
CA2368352A1 (en) Method for treating neurodegeneration
AR025549A1 (en) MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA